Research Reports for Top Traded Penny Stocks: Neostem, CEL-SCI & Advanced Cell Technology, More Reports for UnitedHealth, Crocs & Ciena


Pennystocksinsiders.com (PSI) has issued Equity Research for top traded penny stocks: Neostem (AMEX:NBS), CEL-SCI (AMEX:CVM), Advanced Cell Technology (OTC:ACTC). More reports for UnitedHealth (NYSE:UNH), Crocs (NASDAQ:CROX) & Ciena (NASDAQ:CIEN).
 
Investors should not just focus on stock price or volume momentum when trading penny stocks; it is important to pay attention to see if there is any insider trading in the penny stocks companies before placing a buy order.  Watch more tips on how to use insider trading data to make profitable trades here.
 
(Read full report by clicking the link below, you may need to copy and paste the full link to your browser.)
 
Research Report Highlights:
 
Neostem Inc. (AMEX:NBS): CEO Granted Options Every 2  Weeks
 
Insider Trade Signals: NeoStem, Inc. (NeoStem) is an international biopharmaceutical company with global research and development capabilities and operations in three business units: U.S. adult stem cells, China adult stem cells and China pharmaceuticals, primarily antibiotics. PSI found company CEO, Robin Smith, granted options every two weeks. Want to know just how much better returns these insiders are seeing?

Read Full Report: http://www.Pennystocksinsiders.com/PR/102511B/NBS/Neostem.pdf
 
CEL-SCI Corporation (AMEX:CVM): Struggled Away 52-week Low Price for 2 Weeks
 
Insider Trade Signals: CEL-SCI Corporation announces the closing of its $4 million registered direct offering of common stock and warrants on Oct 7. The losing streak maybe stops today. Want to track the insiders' trading activities moving forward?

Read Full Report: http://www.Pennystocksinsiders.com/PR/102511B/CVM/CEL-SCI.pdf
 
Advanced Cell Technology, Inc. (OTC:ACTC): CSO Sold His Shares
 
Insider Trade Signals: Currently ACTC is trapped between the epic struggles that plague most speculative biotech companies. On one side is the ground breaking science that ACTC is bringing to the table, in the form of a therapy made from embryonic stem cells to treat patients with macular degeneration. Unfortunately all this good news slams head on into ACTC continuing financial and legal woes. Though this is not the worst of times for the company when all things are considered, it is certainly giving investors much anxiety. Want to know when insiders starting selling? Get an email alert for the latest insider buying/selling by subscribing for free below.

Read Full Report: http://www.Pennystocksinsiders.com/PR/102511B/ACTC/AdvancedCellTechnology.pdf
 
Today Pennystocksinsiders.com also released other research reports for:
 
UnitedHealth Group Inc. (NYSE:UNH)
Read Full Report: http://www.Pennystocksinsiders.com/PR/102511B/UNH/UnitedHealth.pdf
 
Crocs, Inc. (NASDAQ:CROX)
Read Full Report: http://www.Pennystocksinsiders.com/PR/102511B/CROX/Crocs.pdf
 
Ciena Corporation (NASDAQ:CIEN)
Read Full Report: http://www.Pennystocksinsiders.com/PR/102511B/CIEN/Ciena.pdf
 
More Individual Stock Reports & Sector Reports:
http://www.Pennystocksinsiders.com/mediaroom/
 
Insider Filing Source Reference: All observations, analysis and reports are based on public information released by the U.S. Securities and Exchange Commission.
 
About Pennystocksinsiders.com:
 
Pennystocksinsiders.com features a team of experienced data analysts striving to provide the investment community with the tools, software, and data necessary to carry out more effective investment research.
 
Important Disclaimer:
Please visit http://www.Pennystocksinsiders.com/disclaimers/index.php for details.
 
CONTACT: Pennystocksinsiders.com, support@Pennystocksinsiders.com, +1-778-2976120
 
SOURCE  Pennystocksinsiders.com
Source:
pennystocksinsiders.com
http://www.pennystocksinsiders.com/mediaroom/index.php

Reported on Oct 25, 2011

 
More Insider News ...